Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection
Open Access
- 28 September 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9), e46518
- https://doi.org/10.1371/journal.pone.0046518
Abstract
The phosphoinositide 3-kinase (PI3K) signaling pathway is significantly altered in a wide variety of human cancers, driving cancer cell growth and survival. Consequently, a large number of PI3K inhibitors are now in clinical development. To begin to improve the selection of patients for treatment with PI3K inhibitors and to identify de novo determinants of patient response, we sought to identify and characterize candidate genomic and phosphoproteomic biomarkers predictive of response to the selective PI3K inhibitor, GDC-0941, using the NCI-60 human tumor cell line collection. In this study, sixty diverse tumor cell lines were exposed to GDC-0941 and classified by GI50 value as sensitive or resistant. The most sensitive and resistant cell lines were analyzed for their baseline levels of gene expression and phosphorylation of key signaling nodes. Phosphorylation or activation status of both the PI3K-Akt signaling axis and PARP were correlated with in vitro response to GDC-0941. A gene expression signature associated with in vitro sensitivity to GDC-0941 was also identified. Furthermore, in vitro siRNA-mediated silencing of two genes in this signature, OGT and DDN, validated their role in modulating sensitivity to GDC-0941 in numerous cell lines and begins to provide biological insights into their role as chemosensitizers. These candidate biomarkers will offer useful tools to begin a more thorough understanding of determinants of patient response to PI3K inhibitors and merit exploration in human cancer patients treated with PI3K inhibitors.Keywords
This publication has 43 references indexed in Scilit:
- Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytesProceedings of the National Academy of Sciences of the United States of America, 2007
- MicroRNA expression profiles for the NCI-60 cancer cell panelMolecular Cancer Therapeutics, 2007
- Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray studyMolecular Cancer Therapeutics, 2007
- Mutation analysis of 24 known cancer genes in the NCI-60 cell line setMolecular Cancer Therapeutics, 2006
- The NCI60 human tumour cell line anticancer drug screenNature Reviews Cancer, 2006
- Comparative gene marker selection suiteBioinformatics, 2006
- Roadmap for Developing and Validating Therapeutically Relevant Genomic ClassifiersJournal of Clinical Oncology, 2005
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Targeting the checkpoint kinases: chemosensitization versus chemoprotectionNature Reviews Cancer, 2004
- O-GlcNAc Modification Is an Endogenous Inhibitor of the ProteasomeCell, 2003